Changes in mother’s LDL-C values according to modification of lipid-lowering therapy
| . | LDL-C (mg/dL) . |
|---|---|
| No lipid-lowering therapy at HeFH diagnosis (44 weeks before the start of gestation) | 364 |
| High-intensity statin plus ezetimibe (25 weeks before the start of gestation) | 191 |
| Three months after the first injection of inclisiran (13 weeks before the start of gestation) | 103 |
| No lipid-lowering therapy (soon after the child’s birth) | 391 |
| Three months after the complete resumption of lipid-lowering treatment (8 months after the child’s birth) | 75 |
| . | LDL-C (mg/dL) . |
|---|---|
| No lipid-lowering therapy at HeFH diagnosis (44 weeks before the start of gestation) | 364 |
| High-intensity statin plus ezetimibe (25 weeks before the start of gestation) | 191 |
| Three months after the first injection of inclisiran (13 weeks before the start of gestation) | 103 |
| No lipid-lowering therapy (soon after the child’s birth) | 391 |
| Three months after the complete resumption of lipid-lowering treatment (8 months after the child’s birth) | 75 |
LDL-C, LDL cholesterol; HeFH, heterozygous familial hypercholesterolaemia.
Changes in mother’s LDL-C values according to modification of lipid-lowering therapy
| . | LDL-C (mg/dL) . |
|---|---|
| No lipid-lowering therapy at HeFH diagnosis (44 weeks before the start of gestation) | 364 |
| High-intensity statin plus ezetimibe (25 weeks before the start of gestation) | 191 |
| Three months after the first injection of inclisiran (13 weeks before the start of gestation) | 103 |
| No lipid-lowering therapy (soon after the child’s birth) | 391 |
| Three months after the complete resumption of lipid-lowering treatment (8 months after the child’s birth) | 75 |
| . | LDL-C (mg/dL) . |
|---|---|
| No lipid-lowering therapy at HeFH diagnosis (44 weeks before the start of gestation) | 364 |
| High-intensity statin plus ezetimibe (25 weeks before the start of gestation) | 191 |
| Three months after the first injection of inclisiran (13 weeks before the start of gestation) | 103 |
| No lipid-lowering therapy (soon after the child’s birth) | 391 |
| Three months after the complete resumption of lipid-lowering treatment (8 months after the child’s birth) | 75 |
LDL-C, LDL cholesterol; HeFH, heterozygous familial hypercholesterolaemia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
